Resseptor Therapeutics

Resseptor Therapeutics is developing T-Cell Receptor (TCR) platform technology, engineering therapies for treatment of cancer, inflammation and autoimmune disease. Their pioneering platform technology enhances the immune system’s ability to identify and respond to tissues, malignancies and pathogens, potentially revolutionising treatments and changing the lives of people with autoimmune diseases, cancer and challenging inflammatory conditions.

Year established: 2023
Lead Researcher: Stephen Daley
Website: resseptor.com